BeOne Medicines Ltd. (ONC) Stock Analysis and Metrics

BeOne Medicines

NASDAQ: ONC

$325.61 ▼ -1.16 (-0.35%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap471.64 Bn

P/E919.34

P/S82.18

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)959.06 Mn

Revenue Growth (1y) (Qtr)35.46

Add ratio to table…

About

BeOne Medicines Ltd. is a global oncology company that discovers and develops innovative cancer treatments for patients worldwide. The company focuses on hematology and solid tumor indications building a portfolio of wholly owned and in licensed products. Its pipeline includes novel small molecules antibody drug conjugates and bispecific therapies aimed at addressing unmet medical needs. BeOne Medicines Ltd. generates revenue primarily from sales of its approved medicines…

Investment Thesis

▲ Bull case

BeOne Medicines' sustained leadership in chronic lymphocytic leukemia (CLL) is underpinned by the unmatched long-term efficacy and safety profile of BRUKINSA (zanubrutinib), which continues to demonstrate superior progression-free survival versus bendamustine-rituximab in the SEQUOIA trial with a median follow-up of 84 months and unprecedented PFS outcomes that reinforce its role as the foundational BTK inhibitor; this durability allows physicians and patients to maintain confidence in first-line treatment decisions over the long arc of therapy, directly supporting durable market share gains and pricing power in a $10 billion+ global CLL market where treatment sequencing and long-term disease control are paramount differentiators.
The company's next-generation hematology franchise, anchored by the FDA-approved BEQALZI (sonrotoclax) and the BRUKINSA plus sonrotoclax (ZS) combination, represents a significant yet underappreciated catalyst for growth, as Phase 1/1b data show unprecedented rates and kinetics of undetectable minimal residual disease (uMRD) in treatment-naïve CLL, including high-risk cytogenetics, positioning ZS as a potential time-limited, curative-intent regimen that could disrupt the current standard of care and capture substantial value from the venetoclax-obinutuzumab (VO) market, which generates over $2 billion annually in CLL alone.
BeOne's solid tumor portfolio is gaining meaningful traction beyond hematology, particularly with TEVIMBRA (tislelizumab) and ZIIHERA (zanidatamab) in HER2-positive gastroesophageal adenocarcinoma (GEA), where the HERIZON-GEA-01 trial demonstrated a statistically significant overall survival benefit with a median OS of 26.4 months in the triplet arm—unprecedented in this disease—and benefit observed regardless of PD-L1 status, which expands the addressable patient population and supports the potential for this regimen to become a new standard of care, especially given the FDA's Priority Review and Breakthrough Therapy Designation for the sBLA submission, accelerating pathways to approval in key markets including the U.S. and China.
The company's internal clinical development superhighway, characterized by vertically integrated capabilities and a global team of nearly 6,000 colleagues, enables faster, more cost-effective drug development, as evidenced by advancing 15 new molecular entities into the clinic in the past 18 months and planning to add eight to 10 NMEs per year starting in 2026; this operational edge reduces time and cost to market, increases success rates in clinical trials, and supports sustainable pipeline productivity that is difficult for competitors to replicate, directly contributing to long-term revenue diversification beyond BRUKINSA.
Financial results for Q1 2026 reveal strong operating leverage, with GAAP income from operations increasing 2,151% year-over-year to $250 million and adjusted income from operations rising 197% to $414 million, driven by 35% total revenue growth to $1.5 billion and expanding gross margin to 89% from 85% in the prior year, reflecting a favorable product mix shift toward higher-margin BRUKINSA and productivity improvements that are expected to persist through 2026, supporting the raised full-year guidance of $6.3–$6.5 billion in revenue and $750–$850 million in GAAP operating income.

BeOne Medicines' sustained leadership in chronic lymphocytic leukemia (CLL) is underpinned by the unmatched long-term efficacy and safety profile of BRUKINSA (zanubrutinib), which continues to demonstrate superior progression-free survival versus bendamustine-rituximab in the SEQUOIA trial with a median follow-up of 84 months and unprecedented PFS outcomes that reinforce its role as the foundational BTK inhibitor; this durability allows physicians and patients to maintain confidence in first-line treatment decisions over the long arc of therapy, directly supporting durable market share gains and pricing power in a $10 billion+ global CLL market where treatment sequencing and long-term disease control are paramount differentiators.
The company's next-generation hematology franchise, anchored by the FDA-approved BEQALZI (sonrotoclax) and the BRUKINSA plus sonrotoclax (ZS) combination, represents a significant yet underappreciated catalyst for growth, as Phase 1/1b data show unprecedented rates and kinetics of undetectable minimal residual disease (uMRD) in treatment-naïve CLL, including high-risk cytogenetics, positioning ZS as a potential time-limited, curative-intent regimen that could disrupt the current standard of care and capture substantial value from the venetoclax-obinutuzumab (VO) market, which generates over $2 billion annually in CLL alone.
BeOne's solid tumor portfolio is gaining meaningful traction beyond hematology, particularly with TEVIMBRA (tislelizumab) and ZIIHERA (zanidatamab) in HER2-positive gastroesophageal adenocarcinoma (GEA), where the HERIZON-GEA-01 trial demonstrated a statistically significant overall survival benefit with a median OS of 26.4 months in the triplet arm—unprecedented in this disease—and benefit observed regardless of PD-L1 status, which expands the addressable patient population and supports the potential for this regimen to become a new standard of care, especially given the FDA's Priority Review and Breakthrough Therapy Designation for the sBLA submission, accelerating pathways to approval in key markets including the U.S. and China.
The company's internal clinical development superhighway, characterized by vertically integrated capabilities and a global team of nearly 6,000 colleagues, enables faster, more cost-effective drug development, as evidenced by advancing 15 new molecular entities into the clinic in the past 18 months and planning to add eight to 10 NMEs per year starting in 2026; this operational edge reduces time and cost to market, increases success rates in clinical trials, and supports sustainable pipeline productivity that is difficult for competitors to replicate, directly contributing to long-term revenue diversification beyond BRUKINSA.
Financial results for Q1 2026 reveal strong operating leverage, with GAAP income from operations increasing 2,151% year-over-year to $250 million and adjusted income from operations rising 197% to $414 million, driven by 35% total revenue growth to $1.5 billion and expanding gross margin to 89% from 85% in the prior year, reflecting a favorable product mix shift toward higher-margin BRUKINSA and productivity improvements that are expected to persist through 2026, supporting the raised full-year guidance of $6.3–$6.5 billion in revenue and $750–$850 million in GAAP operating income.

▼ Bear case

BeOne Medicines' reliance on BRUKINSA as a primary revenue driver presents concentration risk, as the drug faces intensifying competition from next-generation BTK inhibitors and degraders, including pirtobrutinib—which is being evaluated in a head-to-head Phase 3 trial against BGB-16673—and the potential for resistance mechanisms to emerge over long-term use, which could erode BRUKINSA's durability advantage in CLL despite its current long-term data, especially if rival therapies demonstrate superior safety or fixed-duration profiles that appeal to patients seeking time-limited treatment.
The commercial potential of BEQALZI (sonrotoclax) in mantle cell lymphoma (MCL) remains constrained by its accelerated approval status, which requires confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL trial, and the drug's safety profile includes significant risks such as tumor lysis syndrome (occurring in 7% of patients in the safety population), serious infections (14%), and Grade 3/4 neutropenia (18%), which may limit adoption in real-world settings, particularly among elderly or comorbid patients, and could hinder its ability to displace established therapies like acalabrutinib or zanubrutinib-based regimens in R/R MCL.
While the HERIZON-GEA-01 trial shows promise for TEVIMBRA and ZIIHERA in HER2-positive GEA, the regimen's clinical benefit is modest in absolute terms, with a median overall survival improvement of only 2.0 months over zanidatamab plus chemotherapy and 20.0 months over trastuzumab plus chemotherapy, and the safety profile includes substantial toxicity, with Grade ≥3 treatment-related adverse events occurring in 71.8% of patients in the triplet arm and diarrhea leading to discontinuation in 4.1%, which may limit uptake in community oncology settings where tolerability is a key factor, especially given the availability of alternative HER2-targeted agents with more favorable risk-benefit profiles.
BeOne's expanding pipeline, while extensive, carries execution risk, as the company plans to advance eight to 10 new molecular entities into the clinic annually starting in 2026, yet its historical success rate in converting early-stage assets to approval remains unproven at scale, and the increasing investment in R&D—up 12% year-over-year to $541 million in Q1 2026—may not translate into proportional returns if clinical programs fail to meet endpoints or face regulatory delays, particularly for solid tumor assets like BGB-B2033 in hepatocellular carcinoma, which targets a heavily pretreated population with historically poor response rates to monotherapy approaches.
Macroeconomic and geopolitical pressures, including foreign exchange volatility and pricing scrutiny in key markets such as the U.S. and Europe, could constrain revenue growth despite the company's guidance of $6.3–$6.5 billion for full-year 2026, as government-led cost-containment measures and increasing biosimilar competition in oncology may pressure pricing for established products like BRUKINSA, while the company's heavy reliance on third-party manufacturers and collaborators for commercialization introduces supply chain and execution vulnerabilities that could disrupt launch timelines for new indications, particularly in international markets where regulatory alignment remains complex and time-consuming.

BeOne Medicines' reliance on BRUKINSA as a primary revenue driver presents concentration risk, as the drug faces intensifying competition from next-generation BTK inhibitors and degraders, including pirtobrutinib—which is being evaluated in a head-to-head Phase 3 trial against BGB-16673—and the potential for resistance mechanisms to emerge over long-term use, which could erode BRUKINSA's durability advantage in CLL despite its current long-term data, especially if rival therapies demonstrate superior safety or fixed-duration profiles that appeal to patients seeking time-limited treatment.
The commercial potential of BEQALZI (sonrotoclax) in mantle cell lymphoma (MCL) remains constrained by its accelerated approval status, which requires confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL trial, and the drug's safety profile includes significant risks such as tumor lysis syndrome (occurring in 7% of patients in the safety population), serious infections (14%), and Grade 3/4 neutropenia (18%), which may limit adoption in real-world settings, particularly among elderly or comorbid patients, and could hinder its ability to displace established therapies like acalabrutinib or zanubrutinib-based regimens in R/R MCL.
While the HERIZON-GEA-01 trial shows promise for TEVIMBRA and ZIIHERA in HER2-positive GEA, the regimen's clinical benefit is modest in absolute terms, with a median overall survival improvement of only 2.0 months over zanidatamab plus chemotherapy and 20.0 months over trastuzumab plus chemotherapy, and the safety profile includes substantial toxicity, with Grade ≥3 treatment-related adverse events occurring in 71.8% of patients in the triplet arm and diarrhea leading to discontinuation in 4.1%, which may limit uptake in community oncology settings where tolerability is a key factor, especially given the availability of alternative HER2-targeted agents with more favorable risk-benefit profiles.
BeOne's expanding pipeline, while extensive, carries execution risk, as the company plans to advance eight to 10 new molecular entities into the clinic annually starting in 2026, yet its historical success rate in converting early-stage assets to approval remains unproven at scale, and the increasing investment in R&D—up 12% year-over-year to $541 million in Q1 2026—may not translate into proportional returns if clinical programs fail to meet endpoints or face regulatory delays, particularly for solid tumor assets like BGB-B2033 in hepatocellular carcinoma, which targets a heavily pretreated population with historically poor response rates to monotherapy approaches.
Macroeconomic and geopolitical pressures, including foreign exchange volatility and pricing scrutiny in key markets such as the U.S. and Europe, could constrain revenue growth despite the company's guidance of $6.3–$6.5 billion for full-year 2026, as government-led cost-containment measures and increasing biosimilar competition in oncology may pressure pricing for established products like BRUKINSA, while the company's heavy reliance on third-party manufacturers and collaborators for commercialization introduces supply chain and execution vulnerabilities that could disrupt launch timelines for new indications, particularly in international markets where regulatory alignment remains complex and time-consuming.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product Name Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product Name Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password